Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04526899 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
A Phase 2 study of Unresectable Melanoma and Melanoma Stage IV, sponsored by BioNTech SE.
- Completed
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
- 20
- Study locations
NCT04526899 is a Phase 2 study of Unresectable Melanoma and Melanoma Stage IV that has completed, run by BioNTech SE. The registered enrollment target is 184 participants, above the 134-participant average among 24 other Unresectable Melanoma trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT04526899, a Phase 2 study of Unresectable Melanoma and Melanoma Stage IV, has completed, sponsored by BioNTech SE.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death ligand 1 (PD-L1)-refractory/relapsed patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent calibrator arms. Patients will be randomized in a 2:1:1 ratio to Arm 1 (BNT111 + cemiplimab) and calibrator Arm 2 (BNT111 monotherapy), and Arm 3 (cemiplimab monotherapy). Patients in single agent calibrator arms (Arms 2 and 3), who experience centrally verified disease progression under single agent treatment, may be offered addition of the other compound to the ongoing treatment after re-consent.
Conditions Studied
Interventions
- BIOLOGICAL Cemiplimab
- BIOLOGICAL BNT111
Study Locations (20)
Other
- Border Medical Oncology - East Albury
- Gold Coast Hospital - Southport
- Melanoma Institute Australia - Sydney
- Klinik für Dermatologie, Dermatochirurgie, Allergologie, Klinikum Bremen-Ost, Gesundheitnord GmbH - Bremen
- Universitätsklinikum Essen (AoR) - Essen
- Universitätsklinikum Freiburg, Klinik füer Dermatologie und Venerologie - Freiburg im Breisgau
- Universitätsklinikum Heidelberg - Heidelberg
- Universitätsklinikum Schleswig-Holstein (UKSH), Campus Kiel Hautkrebszentrum Kiel - Kiel
- Universitätsklinikum Leipzig - Leipzig
- Universitätsmedizin der Johannes Gutenberg Universität Mainz KoeR - Mainz
- Universitätsklinikum Mannheim GmbH - Mannheim
- Klinikum Nürnberg Nord - Nuremberg
- University Hospital Tübingen - Tübingen
- Klinikum der Julius-Maximilians-Universität Würzburg - Würzburg
Arizona
- University Of Arizona College Of Medicine - Tucson
California
- University of California, San Francisco: Helen Diller Family Comprehensive Cancer Center - San Francisco
Florida
- Sylvester Comprehensive Cancer Center/ UMHC - Miami
Nebraska
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Omaha
New Jersey
- Atlantic Health System / Morristown Medical Center - Morristown
Virginia
- Inova Dwight and Martha Schar Cancer Institute - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2021-05-19 |
| Est. Completion | 2025-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04526899
The ClinicalTrials.gov registry entry for NCT04526899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 134-participant average among 24 other Unresectable Melanoma trials with a reported enrollment target (37% higher). The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Unresectable Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT04526899 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04526899 about?
NCT04526899 is a clinical study titled "A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment". This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death ligand 1 (PD-L1)-refractory/relapsed patients with unresectable Stage III o...
What is the current status of trial NCT04526899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2021-05-19. Estimated completion is 2025-11-24.
What conditions does trial NCT04526899 study?
This clinical trial studies the following conditions: Unresectable Melanoma, Melanoma Stage IV, Melanoma Stage III.
What interventions are being tested in trial NCT04526899?
The interventions under investigation include: Cemiplimab (BIOLOGICAL), BNT111 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04526899?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04526899 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
RECRUITING · Phase 2
-
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
RECRUITING · Phase 2
-
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.